Chloramine-T in high-specific-activity radioiodination of antibodies using N-succinimidyl-3-(trimethylstannyl)benzoate as an intermediate

Nuclear Medicine and Biology

Volumn 25, Issue 7, 1998, Pages 659-665

  Lindegren, S ^a,b   Skarnemark, G ^a   Jacobsson, L ^b   Karlsson, B ^c  

^a CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Fujirebio Diagnostics Inc   (Sweden)

Author keywords

Antibodies; Chloramine T; Conjugation; Iodine; Labelling

Indexed keywords

IODINE 125; N SUCCINIMIDYL 3 (TRIMETHYLSTANNYL)BENZOIC ACID; TOSYLCHLORAMIDE SODIUM; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ANTIBODY SPECIFICITY; ARTICLE; CONJUGATION; ISOTOPE LABELING; METHODOLOGY; RADIOCHEMISTRY; RADIOIODINATION; REACTION ANALYSIS;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BENZOATES; CHLORAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; IODINE RADIOISOTOPES; ORGANOTIN COMPOUNDS; RADIOPHARMACEUTICALS; TOSYL COMPOUNDS; TRIMETHYLTIN COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0031712351     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00033-X     Document Type: Article

References (20)

1. 125I-containing acylation agent. Biochem. J. 133:1973;529-539.
2. Ferens J.M., Krohn K.A., Beaumier P.L., Brown J.P., Hellström I., Hellström K.E., et al. High level of iodination of monoclonal antibody fragments for radiotherapy. J. Nucl. Med. 25:1984;367-370.
3. Freaker P.J., Speck J.C. Jr. Protein and cell membrane iodinations with a sparingly soluble chloramide. Biochem. Biophys. Res. Commun. 880:1978;849-857.
4. Garg P.K., Archer G.E. Jr, Bigner D.D., Zalutsky M.R. Synthesis of radioiodinated N-succinimidyl iodobenzoate Optimisation for use in antibody labeling . Int. J. Radiat. Appl. Instrum. Part A. 40:1989;485-489.
5. Garg P.K., Garg S., Zalutsky M.R. N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate Synthesis and potential utility for the radioiodination of monoclonal antibodies . Nucl. Med. Biol. 20:1993;379-387.
6. 131I-labelled human growth hormone of high specific radioactivity. Biochem. J. 89:1963;114-123.
7. Johansson C., Segerén S., Lindholm L. Tumour-growth suppression in nude mice by murine monoclonal antibody Factors hampering successful therapy. Int. J. Cancer. 48:1991;297-304.
8. 125I-labelled monoclonal antibodies Biodistribution in mice carrying human osteosarcoma xenografts . J. Label. Compd. Radiopharm. 34:1994;773-785.
9. Lindmo T., Boven E., Cutitta F., Fedorko F., Bunn P.A. Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods. 72:1984;77-99.
10. Mantovani L., Ménard S., Mezzanzanica D., Miotti S., Pupa S.M., Colnaghi M.I. Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody. Br. J. Cancer. 62:(suppl. X):1990;1517.
11. Matzku S., Kirchegeßner H., Nissen M. Iodination of monoclonal IgG antibodies at sub-stoichiometric level Immunoreactivity changes related to site of iodine incorporation . Nucl. Med. Biol. 14:1987;451-457.
12. Milius R.A., McLaughlin W.H., Lambrecht R.M., Wolf A.P., Carroll, Adelstein S., et al. Organoastatine chemistry Astatination via electrophilic destannylation . Appl. Radiat. Isot. 37:1986;799-802.
13. Miotti S., Alberti S., Facheris P., Mantovani L., Farnaro M., Stella M., et al. Membrane association and shedding of the GPI-anchored Ca-MOv18 antigen in human ovary carcinoma cells. Int. J. Cancer. 51:1992;499-505.
14. Miotti S., Canevari S., Ménard S., Mezzanzanica D., Porro G., Regazzoni M., et al. Characterisation of human ovarian carcinoma associated antigens by novel monoclonal antibodies with tumour-restricted specificity. Int. J. Cancer. 39:1987;297-302.
15. Vaughan A.T.M., Fremlin J.H. The preparation of astatine-labeled proteins using an electrophilic reaction. Int. J. Nucl. Med. Biol. 5:1978;229-230.
16. Wilbur D.S., Hadely S.W., Hylarides M.D., Abrams P.G., Beaumier P.A., et al. Development of a stable radioiodinating agent to label monoclonal antibodies for radiotherapy of cancer. J. Nucl. Med. 30:1989;216-226.
17. 2 fragments with the α-particle-emiting nuclid At-211 Preservation of immunoreactivity and in vivo localizing capacity . Proc. Natl. Acad. Sci. USA. 86:1989;7149-7153.
18. Zalutsky M.R., Narula A.S. A Method for radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. Appl. Radiat. Isot. 38:1987;1051-1055.
19. Zalutsky M.R., Narula A.S. Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl) benzoate Intermediate. Cancer Res. 48:1988;1446-1450.
20. Zalutsky M.R., Noska M.A., Colapinto E.V., Garg P.K., Friedman H.S., Bigner D.D. Enhanced tumour uptake and in vivo stability of a monoclonal antibody using N-succinimidyl 3-(trimethyl-n-butylstannyl)benzoate. Cancer Res. 49:1989;5543-5549.